Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27630437 | 0.86 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL29688674 | 0.85 | LMNA (0.55) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL31652866 | 0.85 | ALDH1A1 (0.76) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL12982799 | 0.85 | LMNA (0.55) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL36091 | 0.85 | ALDH1A1 (0.76) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL16951267 | 0.84 | ALDH1A1 (0.69) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL29810107 | 0.83 | ALDH1A1 (0.73) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL8156286 | 0.83 | ALDH1A1 (0.73) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL36283 | 0.83 | ALDH1A1 (0.73) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL1287590 | 0.83 | ALDH1A1 (0.73) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112374984-A | Preparation process of 2-bromo-4-hydroxyanisole | 苏州求索生物科技有限公司 | 2021-02-19 | — | — | CN | claimed |
| US-12331047-B2 | Synthesis for 3-bromo-5-(2-ethylimidazo[1, 2-alpha]pyridine-3-carbonyl)-2-hydroxybenzonitrile | ATOM THERAPEUTICS CO., LTD (CN) | 2025-06-17 | — | — | US | disclosed |
| CN-119306597-A | Preparation method of aromatic bromo-compound | 阜阳欣奕华制药科技有限公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-3915984-B1 | SYNTHESIS OF 3-BROMO-5-(2-ETHYLIMIDAZO[1,2-ALPHA]PYRIDINE-3-CARBONYL)-2-HYDROXYBENZONITRILE | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2024-10-30 | — | — | EP | disclosed |
| US-20240009189-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2024-01-11 | — | — | US | disclosed |
| CN-116444443-A | Benzoyl-quinazolinone derivative, and preparation method and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2023-07-18 | — | — | CN | disclosed |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| EP-3445348-B1 | FLUORESCENT COMPOUNDS, PRODUCTION METHODS AND USES THEREOF | UNIV AVEIRO (PT) | 2023-06-07 | — | — | EP | disclosed |
| EP-3445348-B1 | FLUORESCENT COMPOUNDS, PRODUCTION METHODS AND USES THEREOF | UNIV AVEIRO (PT) | 2023-06-07 | — | — | EP | disclosed |
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| EP-0861235-A1 | SUBSTITUTED BENZYLAMINOPIPERIDINE COMPOUNDS | PFIZER INC. (US) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997041090-A1 | INORGANIC ION RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-11-06 | — | — | WO | disclosed |
| WO-1997008144-A1 | SUBSTITUTED BENZYLAMINOPIPERIDINE COMPOUNDS | PFIZER PHARMACEUTICALS INC. (JP) | 1997-03-06 | — | — | WO | disclosed |
| EP-0743938-A1 | SUBSTITUTED SPIRO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1995021817-A1 | SUBSTITUTED SPIRO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-08-17 | — | — | WO | disclosed |
| EP-0550576-A1 | PHENYLPYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-07-14 | — | — | EP | disclosed |
| EP-0267670-B1 | OPTICALLY ACTIVE LIQUID CRYSTAL COMPOUND HAVING CYANO GROUP | Chisso Corporation (JP) | 1992-12-23 | — | — | EP | disclosed |
| WO-1992006085-A1 | PHENYLPYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-04-16 | — | — | WO | disclosed |
| US-4886622-A | Optically active liquid crystal compound having cyano group | CHISSO CORPORATION (JP) | 1989-12-12 | — | — | US | disclosed |
| EP-0267670-A1 | Optically active liquid crystal compound having cyano group | Chisso Corporation (JP) | 1988-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | RNASEH1, DNASE1, FEN1 | ALDH1A1 2267/4885CYP1A2 4393/4885CYP2C19 4123/4885 |
| US-20240009189-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, PMP22 | ALDH1A1 741/4885CYP1A2 1630/4885CYP2C19 3305/4885 |
| US-12331047-B2 | Synthesis for 3-bromo-5-(2-ethylimidazo[1, 2-alpha]pyridine-3-carbonyl)-2-hydroxybenzonitrile | CYP1B1, CYP8B1, HAO2 | ALDH1A1 100/4885CYP1A2 51/4885CYP2C19 167/4885 |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | SMN1; SMN2, CLN6, PMP22 | ALDH1A1 741/4885CYP1A2 1630/4885CYP2C19 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.